Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

ClinicalTrials.gov ID: NCT04259255

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04259255. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.

Study identification

NCT ID: NCT04259255
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Shionogi; Industry
Enrollment: 74 participants

Conditions and interventions

Conditions

Interventions

Edaravone (Radicava®/Radicava ORS®) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2019 (Actual)
Primary completion: Nov 24, 2023 (Actual)
Completion: Nov 24, 2024 (Actual)
Last update posted: Jun 30, 2026

2019 – 2024

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 17

Facility	City	State	ZIP	Site status
Barrow Neurological Institute	Phoenix	Arizona	85013	—
UCLA Als Clinic	Los Angeles	California	90024	—
UC Davis Health	Sacramento	California	95817	—
University of California, San Francisco	San Francisco	California	94417	—
University of Colorado	Denver	Colorado	80309	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
University of Florida, Jacksonville -Neurology Research Department	Jacksonville	Florida	32209	—
Mayo Clinic Florida	Jacksonville	Florida	32224	—
University of South Florida	Tampa	Florida	33612	—
Johns Hopkins University	Baltimore	Maryland	21205	—
Massachusetts General Hospital	Boston	Massachusetts	02214	—
Mercy Health	Grand Rapids	Michigan	49503	—
Neurology Associates, P.C.	Lincoln	Nebraska	68506	—
Las Vegas Clinic	Las Vegas	Nevada	89145	—
OhioHealth	Columbus	Ohio	43215	—
Jefferson Weinberg ALS Center	Philadelphia	Pennsylvania	19107	—
Temple University Lewis Katz School of Medicine	Philadelphia	Pennsylvania	19140	—
University of Utah	Salt Lake City	Utah	84112	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04259255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 30, 2026 · Synced Nov 14, 2026